Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive ...
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 monthsBOSTON and ...
The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified...
RBC Capital analyst Conor McNamara maintains Sophia Genetics (NASDAQ:SOPH) with a Outperform and lowers the price target fro...
Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.2...
Guggenheim analyst Subbu Nambi initiates coverage on Sophia Genetics (NASDAQ:SOPH) with a Buy rating and announces Price Tar...
SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today ...
